Package Insert: Information for the User
Nexium 40 mg Powder for Injection and for Infusion
esomeprazole
Read this package insert carefully before starting to use this medication, as it contains important information for you.
Nexiumcontains a medication called esomeprazole that belongs to a group of medications called “proton pump inhibitors”. These work by reducing the amount of acid produced by the stomach.
Nexiumis used for the treatment of the following disorders, when oral treatment is not possible:
Adults
Children and adolescents aged 1 to 18 years
If you are in any of these situations, Nexium will not be administered to you. If you are unsure, consult your doctor, pharmacist or nurse before this medication is administered to you.
Warnings and precautions
Consult your doctor or nurse before Nexium is administered to you if:
Nexium may mask symptoms of other diseases.Therefore, if you observe any of the following events before Nexium is administered to you or after its administration, contact your doctor immediately:
Taking a proton pump inhibitor like Nexium, especially for more than a year, may slightly increase the risk of breaking a hip, wrist or spine. Inform your doctor if you have osteoporosis or are taking corticosteroids (which may increase the risk of osteoporosis).
Rashes and skin symptoms
If you experience a rash, especially on sun-exposed skin areas, consult your doctor as soon as possible, as it may be necessary to interrupt Nexium treatment. Remember to mention any other symptoms you may notice, such as joint pain.
Severe skin rashes have occurred in patients taking esomeprazole (see also section 4). The rash may include mouth ulcers, throat, nose, genital, and conjunctivitis (red and swollen eyes). These severe skin rashes usually appear after symptoms similar to the flu, such as fever, headache, and body aches. The rash may cover large areas of the body with blisters and skin peeling.
If, at any time during treatment (even after several weeks), you develop a rash or any of these skin symptoms, stop taking this medication and contact your doctor immediately.
Use of Nexium with other medications
Inform your doctor or nurse if you are taking, have taken recently, or may need to take any other medication. This includes medications purchased without a prescription. This is because Nexium may affect how some medications work and some medications may influence the effect of Nexium.
Nexium will not be administered to you if you are taking a medication that contains nelfinavir (used for HIV infection).
Inform your doctor if you are using any of the following medications:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before this medication is administered to you. Your doctor will decide if Nexium can be administered to you during this period.
The passage of Nexium into breast milk is unknown. Therefore, do not take Nexium during breastfeeding.
Driving and operating machinery
Nexium is unlikely to affect your ability to drive or use tools or machines. However, rare side effects such as dizziness or blurred vision (see section 4) may occur. Do not drive or use machines if you notice any of these side effects.
Nexiumcan be administered to children and adolescents from 1 to 18years and to adults, including elderly patients.
Use in Adults
Use in Children and Adolescents
If You Are Given More Nexium Than You Should
If you think you have been given too much Nexium, consult your doctor immediately.
In case of overdose or accidental ingestion, contact the Toxicology Information Service. Phone 91 5620420, indicating the medication and the amount administered.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you notice any of the following serious side effects, stop taking Nexium and contact a doctor immediately:
These side effects are rare and may affect up to 1 in 1,000 people.
These side effects are rare and may affect up to 1 in 1,000 people.
These side effects are very rare and may affect up to 1 in 10,000 people.
Other side effects include:
Frequent (may affect up to 1 in 10 people)
Occasional (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (the frequency cannot be estimated from the available data)
In rare cases, Nexium may affect white blood cells, causing immunodeficiency. If you have an infection with symptoms such as severe worsening of the general condition or fever with symptoms of a local infection such as neck pain, throat pain, mouth pain, or difficulty urinating, you should consult your doctor as soon as possible to rule out a decrease in the number of white blood cells (agranulocytosis) through a blood test. It is essential to inform your doctor about your medication in this case.
Reporting side effects
If you experience any type of side effect, consult your doctor, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSistema Español de Farmacovigilancia de medicamentos de Uso Humano:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Store the vial in the outer packaging to protect it from light. However, vials may be stored outside the packaging exposed to interior light for up to 24 hours.
Aspect of the product and content of the package
Nexium is a porous or white to off-white powder. Before it is administered, this is reconstituted into a solution.
Packages: 1 vial, 10 vials.It may only be marketed in some package sizes.
Holder of the marketing authorization and responsible for the manufacture
Holder of the marketing authorization:
Grünenthal Pharma, S.A.
Doctor Zamenhof, 36 – 28027 Madrid, Spain
Responsible for the manufacture
AstraZeneca AB,152 57Södertälje, Sweden
Grünenthal GmbH, Zieglerstrasse 6- D- 52078 Aachen, Germany
This medicine is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Member State | Medicine name |
Austria, Denmark, Finland, Greece, Iceland,Ireland, Italy,Netherlands, Norway,Poland,Spain, Sweden, United Kingdom(Northern Ireland) | Nexium |
Belgium, Luxembourg | Nexiam |
France | Inexium |
Portugal | Nexium I.V. |
Last review date of this leaflet: December 2021
Other sources of information
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
This information is intended solely for healthcare professionals:
Nexium 40mg contains 40mg of esomeprazole, as sodium salt. Each vial also contains edetate disodium and sodium hydroxide (<1mmol of sodium).
The vials are for single use. If the unused solution from the reconstituted vial is not used for a single dose, it must be discarded.
For further information on dosage recommendations and storage conditions, please refer to sections 3 and 5, respectively.
Preparation and administration of the reconstituted solution:
To reconstitute the solution, remove the plastic cap from the top of the Nexium vial and pierce the stopper in the center of the marked circle, keeping the needle in a vertical position, in order to be able to correctly pierce the stopper.
The reconstituted solution for injection or infusion must be transparent and colorless to slightly yellow. It must be visually inspected to detect particles and discoloration before administration and only the transparent solution should be used.
The stability has been demonstrated in terms of physical and chemical stability for 12 hours at 30°C. However, from a microbiological point of view, the product should be used immediately.
Injection of Nexium
For preparing a solution for injection:
Injection of 40mg
To a reconstituted solution of 8mg/ml of esomeprazole: Prepare the solution by adding 5ml of sodium chloride 0.9% for intravenous use to the vial of esomeprazole 40mg.
The reconstituted solution for injection must be administered intravenously over a period of at least 3 minutes.
For further information on the administration of the doses, please refer to the technical data sheet, section 4.2.
Infusion of Nexium
For preparing a solution for infusion:
Infusion 40mg
Dissolve the contents of a vial of esomeprazole 40mg in up to 100ml of sodium chloride 0.9% for intravenous use.
Infusion 80mg
Dissolve the contents of two vials of esomeprazole 40mg in up to 100mlof sodium chloride 0.9% for intravenous use.
For further information on the administration of the dose, please refer to the technical data sheet, section 4.2.
Elimination
Any remaining medicine or waste material should be disposed of in accordance with local procedures.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.